Chiron Corp. v. Genentech, Inc. — Broad Monoclonal Antibody Claims Invalid When Specification Enables Only Murine Antibodies, Not Chimeric or Humanized Forms
The Federal Circuit affirmed invalidity of Chiron’s HER2 antibody patent, holding that claims broadly encompassing chimeric and humanized antibodies were not enabled by a specification that only disclosed murine antibodies, even though the claims were filed years before Herceptin was developed